Lineage Cell Therapeutics Inc. — Director's Dealing 2018

Jul 4, 2018

F ORM 4
---------------	--

[ ] Check this box if no longer subject to Section 16. Form 4 or continue. See Instruction 1(b).

FORM 4 Washington, D.C. 20549

OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Form 5 obligations may UNITED STATES SECURITIES AND EXCHANGE COMMISSION STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES OMB APPROVAL

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
BRADSHER NEAL C	BIOTIME INC [ BTX ]
(Last) (First) (Middle)	3. Date of Earliest Transaction (MM/DD/YYYY)	__ X __ Director __ X __ 10% Owner _ Officer (give title below) ___ Other (specify below)
C/O BROADWOOD CAPITAL INC., 724 FIFTH AVENUE, 9TH FLOOR	7/1/2018
(Street)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line)
NEW YORK, NY 10019 (City) (State) (Zip)		_ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security	2. Trans. Date	2A. Deemed	3. Trans. Code			4. Securities Acquired (A)		5. Amount of Securities Beneficially Owned	6.	7. Nature
(Instr. 3)		Execution	(Instr. 8)			or Disposed of (D)		Following Reported Transaction(s)	Ownership	of Indirect
		Date, if any			(Instr. 3, 4 and 5)			(Instr. 3 and 4)	Form:	Beneficial
									Direct (D)	Ownership
									or Indirect	(Instr. 4)
						(A) or			(I) (Instr.
			Code	V	Amount	(D)	Price		4)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	10. Ownership Form of Derivative Security: Direct (D)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)	or Indirect (I) (Instr. 4)
OPTION TO PURCHASE COMMON SHARES	\$2.06	7/1/2018		A		40000		(1)	6/30/2023	COMMON SHARES	40000	\$0 (2)	40000	D
OPTION TO PURCHASE COMMON SHARES	\$3.15							(3)	6/30/2022	COMMON SHARES	20000		20000	D
OPTION TO PURCHASE COMMON SHARES	\$2.72							(3)	6/30/2021	COMMON SHARES	20000		20000	D
OPTION TO PURCHASE COMMON SHARES	\$3.57							(3)	6/30/2020	COMMON SHARES	20000		20000	D
OPTION TO PURCHASE COMMON SHARES	\$3.11							(3)	6/30/2019	COMMON SHARES	20000		20000	D

Explanation of Responses:

• (1) These options will vest and become exercisable on June 30, 2019, provided, that Neal C. Bradsher remains a member of the issuer's board of directors on that date
• (2) The options were granted to Neal Bradsher by the issuer on July 1, 2018 as director compensation pursuant to resolutions from the minutes of the issuer's board of directors meeting on January 24, 2018.
• (3) These options are currently exercisable.

Reporting Owners

Reporting Owner Name / Address		Relationships
	Director	10% OwnerOfficerOther
BRADSHER NEAL C

Signatures

/s/ Neal C. Bradsher	7/3/2018
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.